Reovirus in cancer therapy: an evidence-based review

@inproceedings{Clements2014ReovirusIC,
  title={Reovirus in cancer therapy: an evidence-based review},
  author={Derek Richard Clements and Erin Helson and Shashi Gujar and Patrick W. K. Lee},
  booktitle={Oncolytic virotherapy},
  year={2014}
}
Reovirus, a double-stranded ribonucleic acid virus and benign human pathogen, preferentially infects and kills cancer cells in its unmodified form, and is one of the leading oncolytic viruses currently undergoing clinical trials internationally. With 32 clinical trials completed or ongoing thus far, reovirus has demonstrated clinical therapeutic applicability against a multitude of cancers, including but not limited to breast cancer, prostate cancer, pancreatic cancer, malignant gliomas… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 82 REFERENCES

A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2011
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Group

NCIC Clinical Trial
  • Reolysin in patients with previously treated advanced or metastatic, non small cell lung cancer receiving standard salvage therapy. Available from: http://www.clinicaltrials. gov/ct2/show/NCT01708993?term=reolysin&rank=4. NLM identifier: NCT01708993. Accessed March 16,
  • 2014
VIEW 1 EXCERPT

Maraba virus as a potent oncolytic vaccine vector.

  • Molecular therapy : the journal of the American Society of Gene Therapy
  • 2014

Oncolytics Biotech Inc. enters into sponsorship agreement with NCIC CTG for randomized phase II study in colorectal cancer [press release

Oncolytics Biotech
  • Calgary: Oncolytics Biotech; 2012 [May 3]. Available from: http://www.oncolyticsbiotech.com/English/ news/press-release-details/2012/Oncolytics-Biotech-Inc-Entersinto-Sponsorship-Agreement-with-NCIC-CTG-for-RandomizedPhase-II-Study-in-Colorectal-Cancer. Accessed March 16,
  • 2014

Phase 2 study of Reolysin in combination with paclitaxel and carboplatin in patients with head and neck carcinoma

Oncolytics Biotech
  • Available from: http://www.clinicaltrials.gov/ct2/show/NCT0075303 8?term=reolysin&rank=13. NLM identifier: NCT00753038. Accessed March
  • 2014